Leqembi Receives Official Approval in Mexico
BioArctic AB's (publ) partner Eisai announced a significant milestone with the approval of Leqembi (lecanemab) for early Alzheimer's disease treatment by the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico. This approval marks an important advancement in the battle against Alzheimer's disease, affecting numerous individuals in need of effective treatment.
Understanding Leqembi and Its Mechanism
Leqembi is a humanized IgG1 monoclonal antibody that selectively targets both soluble and insoluble forms of amyloid-beta (A?) aggregates, which are crucial contributors to Alzheimer's disease pathology. By reducing these toxic aggregates in the brain, Leqembi aims to slow cognitive decline and functional impairment associated with the disease, setting it apart as the first approved treatment with such capabilities.
The Significance of Clinical Trials
The approval of Leqembi is supported by robust data from the large-scale Clarity AD Phase 3 clinical trial, which demonstrated statistically significant results across primary and secondary endpoints. As a testament to its potential, it's estimated that around 1.3 million individuals in Mexico currently suffer from Alzheimer's disease, highlighting the urgent need for effective treatments.
Collaboration Between BioArctic and Eisai
Leqembi's development is the result of a longstanding collaboration between BioArctic and Eisai, originating from research by Professor Lars Lannfelt and his Arctic mutation discovery related to Alzheimer's. This partnership allows BioArctic to jointly commercialize the drug in the Nordic region, reflecting their commitment to addressing this pressing healthcare need.
Global Reach of Leqembi
Leqembi is already available in multiple markets, including the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and Great Britain. This broad approval showcases the global recognition of lecanemab's efficacy in treating Alzheimer's disease.
Ongoing and Future Studies
Eisai is actively pursuing regulatory approvals for lecanemab across 16 additional countries and regions, including the European Union. Recent positive feedback from the Committee for Medicinal Products for Human Use (CHMP) reinforces the likelihood of further approvals. Furthermore, Eisai's ongoing Phase 3 clinical study, AHEAD 3-45, aims to examine lecanemab's effects on preclinical Alzheimer's, showcasing continued research efforts in the field.
Expanding BioArctic's Research Portfolio
In addition to lecanemab, BioArctic is developing a diverse range of therapeutic options targeting neurodegenerative diseases, with innovative technologies like BrainTransporter™, intended to enhance treatment efficacy. This research aims to provide hope for conditions such as Parkinson's disease and ALS.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-oriented biopharmaceutical company dedicated to innovating treatments for neurodegenerative diseases. Their flagship product, Leqembi, exemplifies their commitment to discovering solutions that can alter the course of diseases like Alzheimer's. As they prepare for commercialization efforts, BioArctic is well-positioned to make a significant impact on global health.
Frequently Asked Questions
What is Leqembi used for?
Leqembi is used for the treatment of early stages of Alzheimer's disease, specifically to slow disease progression and cognitive decline.
Where has Leqembi been approved?
Leqembi has received approval in several markets including the U.S., Japan, China, South Korea, and now Mexico.
What clinical trial supported Leqembi's approval?
The approval was supported by data from the Clarity AD Phase 3 clinical trial, which showed significant effectiveness in its endpoints.
Who developed Leqembi?
Leqembi was developed through a collaboration between BioArctic and Eisai, based on foundational research in Alzheimer's disease.
How does Leqembi work?
Leqembi works by targeting and reducing amyloid-beta aggregates in the brain, which are responsible for cognitive decline in Alzheimer's disease.
